Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background: Within Parkinson’s there is a spectrum of clinical features at presentation which may represent sub-types of the disease. However there is no widely accepted consensus of how best to group patients. Objective: Use a data-driven approach to unravel any heterogeneity in the Parkinson’s phenotype in a well-characterised, population-based incidence cohort. Methods: 769 consecutive patients, with mean disease duration of 1.3 years, were assessed using a broad range of motor, cognitive and non-motor metrics. Multiple imputation was carried out using the chained equations approach to deal with missing data. We used an exploratory and then a confirmatory factor analysis to determine suitable domains to include within our cluster analysis. K-means cluster analysis of the factor scores and all the variables not loading into a factor was used to determine phenotypic subgroups. Results: Our factor analysis found three important factors that were characterised by: psychological well-being features; non-tremor motor features, such as posture and rigidity; and cognitive features. Our subsequent five cluster model identified groups characterised by (1) mild motor and non-motor disease (25.4%), (2) poor posture and cognition (23.3%), (3) severe tremor (20.8%), (4) poor psychological well-being, RBD and sleep (18.9%), and (5) severe motor and non-motor disease with poor psychological well-being (11.7%). Conclusion: Our approach identified several Parkinson’s phenotypic sub-groups driven by largely dopaminergic-resistant features (RBD, impaired cognition and posture, poor psychological well-being) that, in addition to dopaminergic-responsive motor features may be important for studying the aetiology, progression, and medication response of early Parkinson’s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“K -means is fairly well established in PD studies which seek to identify sub-types of PD, such as those who are tremor-dominant versus those with rapid motor function decline and cognitive impairment. 15”
From Machine learning for large‐scale wearable sensor data in Parkinson's disease: Concepts, promises, pitfalls, and futures (2016) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herne, H., Cooley, W. W., & Lohnes, P. R. (1973) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344428 · Cited by 35,697
(2012) · Encyclopedia of the Sciences of Learning · doi:10.1007/978-1-4419-1428-6_5195 · Cited by 19,370
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Symptoms such as RBD, which can manifest prior to the onset of motoric symptoms, are characterised pathologically by involvement of the locus coeruleus, subcoeruleus, pedunculopontine and serotonergic raphe nuclei [18].”
BackgroundRUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
O'fallon, W. M. (1973) · Technometrics · doi:10.1080/00401706.1973.10489095 · Cited by 6,289
A dendrite method for cluster analysis
Caliński, T., & Harabasz, J. (1974) · Communications in Statistics · doi:10.1080/03610927408827101 · Cited by 4,480
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Barker, L. (2002) · Technometrics · doi:10.1198/tech.2002.s659 · Cited by 2,477
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Effect of the number of variables on measures of fit in structural equation modeling
Kenny, D. A., & McCoach, D. B. (2003) · Structural Equation Modeling: A Multidisciplinary Journal · doi:10.1207/s15328007sem1003_1 · Cited by 1,231 · cited 1×
“It is likely that our poor goodness of fit is due to the large number of variables in the first two factors [16] and our sample size [12].”
Background
Cited by
Kubota, K. J., Chen, J. A., & Little, M. A. (2016) · Movement Disorders · doi:10.1002/mds.26693 · Cited by 210
De Luca, C. M. G., Elia, A. E., Portaleone, S. M., Cazzaniga, F. A., Rossi, M., Bistaffa, E., De Cecco, E., Narkiewicz, J., Salzano, G., Carletta, O., et al. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0164-x · Cited by 185
Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression
Lawton, M., Ben-Shlomo, Y., May, M. T., Baig, F., Barber, T. R., Klein, J. C., Swallow, D. M. A., Malek, N., Grosset, K. A., Bajaj, N., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318337 · Cited by 177
Self-citationSmartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD
Arora, S., Baig, F., Lo, C., Barber, T. R., Lawton, M. A., Zhan, A., Rolinski, M., Ruffmann, C., Klein, J. C., Rumbold, J., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006366 · Cited by 143
Self-citationFinding useful biomarkers for Parkinson’s disease
Chen-Plotkin, A. S., Albin, R., Alcalay, R., Babcock, D., Bajaj, V., Bowman, D., Buko, A., Cedarbaum, J., Chelsky, D., Cookson, M. R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6003 · Cited by 146
A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease
Silverdale, M., Kobylecki, C., Kass‐Iliyya, L., Martínez‐Martín, P., Lawton, M., Cotterill, S., Chaudhuri, К. R., Morris, H. R., Baig, F., Williams, N. M., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.001 · Cited by 149
Self-citationData-driven subtyping of Parkinson's disease using longitudinal clinical records: a cohort study
Zhang, X., Chou, J., Liang, J., Xiao, C., Zhao, Y., Sarva, H., Henchcliffe, C., & Wang, F. (2019) · Scientific Reports · doi:10.1038/s41598-018-37545-z · Cited by 137
Bloem, B. R., Marks, W. J., Silva de Lima, A. L., Kuijf, M. L., van Laar, T., Jacobs, B. P. F., Verbeek, M. M., Helmich, R. C., van de Warrenburg, B. P., Evers, L. J. W., et al. (2019) · BMC Neurology · doi:10.1186/s12883-019-1394-3 · Cited by 117
Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells
Smith, A. M., Depp, C., Ryan, B. J., Johnston, G. I., Alegre‐Abarrategui, J., Evetts, S., Rolinski, M., Baig, F., Ruffmann, C., Simon, A. K., et al. (2018) · Movement Disorders · doi:10.1002/mds.104 · Cited by 116
Self-citationSeverson, K., Chahine, L. M., Smolensky, L., Dhuliawala, M., Frasier, M. A., Ng, K., Ghosh, S., & Hu, J. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00101-1 · Cited by 115
The Luxembourg Parkinson’s Study: A Comprehensive Approach for Stratification and Early Diagnosis
Hipp, G., Vaillant, M., Diederich, N. J., Roomp, K., Satagopam, V., Banda, P., Sandt, E., Mommaerts, K., Schmitz, S. K., Longhino, L., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00326 · Cited by 95
Self-citationBlood Biomarkers With Parkinson's Disease Clusters and Prognosis: The Oxford Discovery Cohort
Lawton, M., Baig, F., Toulson, G., Morovat, A., Evetts, S. G., Ben‐Shlomo, Y., & Hu, M. T. (2019) · Movement Disorders · doi:10.1002/mds.27888 · Cited by 95
Self-citationCruz, B. G. S., Husch, A., & Hertel, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1216163 · Cited by 90
The Dementias Platform UK (DPUK) Data Portal
Bauermeister, S., Orton, C., Thompson, S., Barker, R. A., Bauermeister, J. R., Ben‐Shlomo, Y., Brayne, C., Burn, D. J., Campbell, A., Calvin, C. M., et al. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00633-4 · Cited by 86
Self-citationPatterns of grey matter loss associated with motor subscores in early Parkinson's disease
Li, X., Xing, Y., Martín‐Bastida, A., Piccini, P. P., & Auer, D. P. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.11.009 · Cited by 85
Alafuzoff, I. I., & Hartikainen, P. H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00024-9 · Cited by 85
Closing the loop for patients with Parkinson disease: where are we?
Teymourian, H., Tehrani, F., Longardner, K., Mahato, K., Podhajny, T., Moon, J., Goud, K. Y., Sempionatto, J. R., Litvan, I., & Wang, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00674-1 · Cited by 83
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease
Erro, R., Picillo, M., Vitale, C., Palladino, R., Amboni, M., Moccia, M., Pellecchia, M. T., & Barone, P. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.04.026 · Cited by 76
Human behavioral assessments in current research of Parkinson’s disease
Asakawa, T., Fang, H., Sugiyama, K., Nozaki, T., Kobayashi, S. S., Hong, Z., Suzuki, K., Mori, N., Yang, Y., Hua, F., et al. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.036 · Cited by 78
A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
Mollenhauer, B., Batrla, R., El‐Agnaf, O. M. A., Galasko, D. R., Lashuel, H. A., Merchant, K., Shaw, L. M., Selkoe, D. J., Umek, R. M., Vanderstichele, H., et al. (2017) · Movement Disorders · doi:10.1002/mds.27090 · Cited by 75
Schwamborn, J. C. (2018) · Stem Cells and Development · doi:10.1089/scd.2017.0289 · Cited by 69
Immunotherapies in Huntington's disease and α-Synucleinopathies
Fatoba, O., Ohtake, Y., Itokazu, T., & Yamashita, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00337 · Cited by 42
New concepts in the pathogenesis and presentation of Parkinson’s disease
Sauerbier, A., Qamar, M. A., Rajah, T., & Chaudhuri, К. R. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-365 · Cited by 66
Predicting motor, cognitive & functional impairment in Parkinson's
Lo, C., Arora, S., Baig, F., Lawton, M., Mouden, C. E., Barber, T. R., Ruffmann, C., Klein, J. C., Brown, P., Ben‐Shlomo, Y., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50853 · Cited by 66
Self-citationContinuous Real-World Gait Monitoring in Idiopathic REM Sleep Behavior Disorder
Din, S. D., Yarnall, A. J., Barber, T. R., Lo, C., Crabbe, M. J. C., Rolinski, M., Baig, F., Hu, M. T., & Rochester, L. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191773 · Cited by 66
Self-citationUpdate on the Management of Parkinson’s Disease for General Neurologists
Pirtošek, Z., Bajenaru, O. A., Kovács, N., Milanov, I. G., Relja, M., & Škorvánek, M. (2020) · Parkinson s Disease · doi:10.1155/2020/9131474 · Cited by 66
Multimodal phenotypic axes of Parkinson’s disease
Markello, R. D., Shafiei, G., Tremblay, C., Postuma, R. B., Dagher, A., & Mišić, B. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-020-00144-9 · Cited by 62
Jellinger, K. A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02028-6 · Cited by 60
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective
Stephenson, D. T., Badawy, R., Mathur, S., Tome, M. B., & Rochester, L. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202428 · Cited by 60
Ruffmann, C., Bengoa‐Vergniory, N., Poggiolini, I., Ritchie, D. L., Hu, M. T., Alegre‐Abarrategui, J., & Parkkinen, L. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12486 · Cited by 59
Self-citationFunctional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients
Micco, R. D., Agosta, F., Basaia, S., Siciliano, M., Cividini, C., Tedeschi, G., Filippi, M., & Tessitore, A. (2021) · Movement Disorders · doi:10.1002/mds.28541 · Cited by 59
Working Memory in Alzheimer’s Disease and Parkinson’s Disease
Zokaei, N., & Husain, M. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_103 · Cited by 57
Robust identification of Parkinson's disease subtypes using radiomics and hybrid machine learning
Salmanpour, M. R., Shamsaei, M., Saberi, A., Hajianfar, G., Soltanian-Zadeh, H., & Rahmim, A. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104142 · Cited by 54
Parkinson disease clinical subtypes: key features & clinical milestones
Campbell, M. C., Myers, P. S., Weigand, A. J., Foster, E. R., Cairns, N. J., Jackson, J. J., Lessov‐Schlaggar, C. N., & Perlmutter, J. S. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51102 · Cited by 53
Identification of potential urine biomarkers in idiopathic parkinson's disease using NMR
Kumari, S., Kumaran, S. S., Goyal, V., Sharma, R. K., Sinha, N., Dwivedi, S. N., Srivastava, A. K., & Jagannathan, N. R. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.08.005 · Cited by 48
Cerebrospinal fluid biomarker for Parkinson's disease: An overview
Maass, F., Schulz, I., Lingor, P., Mollenhauer, B., & Bähr, M. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.005 · Cited by 47
Lee, S. H., Park, S., Yeo, S. S., Kwon, O., Lee, M., Yoo, H.-R., Ahn, E. K., Jang, J. Y., & Jang, J.-H. (2022) · Diagnostics · doi:10.3390/diagnostics12010112 · Cited by 44
The future of drug development: the paradigm shift towards systems therapeutics
Danhof, M., Klein, K., Stolk, P., Aitken, M. L., & Leufkens, H. G. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.002 · Cited by 44
Two-year clinical progression in focal and diffuse subtypes of Parkinson’s disease
Johansson, M. E., van Lier, N. M., Kessels, R. P. C., Bloem, B. R., & Helmich, R. C. G. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00466-4 · Cited by 42
Biomarkers of Parkinson’s Disease: From Basic Research to Clinical Practice
Ma, Z.-L., Wang, Z., Zhang, F., Liu, H. P., Mao, L.-H., & Yuan, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.1005 · Cited by 42
A Systematic Review of Parkinson’s Disease Cluster Analysis Research
Hendricks, R. M., & Khasawneh, M. T. (2021) · Aging and disease · doi:10.14336/ad.2021.0519 · Cited by 40
Burk, B. R., & Watts, C. R. (2018) · Journal of Voice · doi:10.1016/j.jvoice.2018.01.016 · Cited by 40
Magnetic resonance imaging as a potential biomarker for Parkinson's disease
Tuite, P. (2015) · Translational research · doi:10.1016/j.trsl.2015.12.006 · Cited by 40
Application of Wearable Sensors in Parkinson’s Disease: State of the Art
Bougea, A. M. (2025) · Journal of Sensor and Actuator Networks · doi:10.3390/jsan14020023 · Cited by 39
Klietz, M., Bronzlik, P., Nösel, P., Wegner, F., Dressler, D. W., Dadak, M., Maudsley, A. A., Sheriff, S., Lanfermann, H., & Ding, X.-Q. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00777 · Cited by 37
Whole-exome sequencing of 228 patients with sporadic Parkinson’s disease
Sandor, C., Honti, F., Haerty, W., Szewczyk‐Królikowski, K., Tomlinson, P. R., Evetts, S., Millin, S., Keane, T., McCarthy, S., Durbin, R. M., et al. (2017) · Scientific Reports · doi:10.1038/srep41188 · Cited by 35
Self-citationParkinson’s Disease in the Era of Personalised Medicine: One Size Does Not Fit All
Ryden, L. E., & Lewis, S. J. G. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0624-5 · Cited by 34
Wilson, E. N., Umans, J., Swarovski, M. S., Minhas, P. S., Mendiola, J. H., Midttun, Ø., Ulvik, A., Shahid, M., Linortner, P., Mhatre, S. D., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00964-7 · Cited by 33
Nonmotor Subtyping in Parkinson's Disease
Sauerbier, A., Rosa‐Grilo, M., Qamar, M. A., & Chaudhuri, К. R. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.011 · Cited by 32
Dietiker, C., Kim, S., Zhang, Y., & Christine, C. W. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18049 · Cited by 29
Computational systems biology approaches for Parkinson’s disease
Glaab, E. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2734-5 · Cited by 28
Deep phenotyping for precision medicine in Parkinson's disease
Schalkamp, A., Rahman, N., Monzón‐Sandoval, J., & Sandor, C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049376 · Cited by 27
Peripheral Neuropathy Research Registry: A prospective cohort
Thomas, S., Ajroud‐Driss, S., Dimachkie, M. M., Gibbons, C. H., Freeman, R. L., Simpson, D. M., Singleton, J. R., Smith, A. G., PNRR Study Group, & Höke, A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12301 · Cited by 27
Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment
Gozalbo, A. S., Rodríguez‐Blázquez, C., Forjaz, M. J., & Martínez‐Martín, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00731 · Cited by 27
Potential Metabolomic Linkage in Blood between Parkinson’s Disease and Traumatic Brain Injury
Fiandaca, M. S., Gross, T. J., Johnson, T. M., Hu, M. T., Evetts, S. G., Wade‐Martins, R., Merchant‐Borna, K., Bazarian, J. J., Cheema, A. K., Mapstone, M. E., et al. (2018) · Metabolites · doi:10.3390/metabo8030050 · Cited by 26
Self-citationA Personalized Approach to Parkinson’s Disease Patients Based on Founder Mutation Analysis
Giladi, N., Mirelman, A., Thaler, A., & Orr‐Urtreger, A. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00071 · Cited by 25
Neurodegenerative Diseases and Ageing
Walker, L., McAleese, K. E., Erskine, D., & Attems, J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_4 · Cited by 24
Precision medicine for Parkinson’s disease: The subtyping challenge
Frasier, M. A., Fiske, B. K., & Sherer, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1064057 · Cited by 21
Toward Personalized Medicine Approaches for Parkinson Disease Using Digital Technologies
Khanna, A., & Jones, G. B. (2023) · JMIR Formative Research · doi:10.2196/47486 · Cited by 20
Two-hundred Years Later: Is Parkinson’s Disease a Single Defined Entity?
Rodríguez‐Violante, M., Cervantes‐Arriaga, A., Fahn, S., & TOLOSA, E. S. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002291 · Cited by 20
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson’s disease
Ygland, E., & Puschmann, A. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00208-4 · Cited by 18
Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
Griffanti, L., Klein, J. C., Szewczyk‐Królikowski, K., Menke, R., Rolinski, M., Barber, T. R., Lawton, M., Evetts, S. G., Begeti, F., Crabbe, M. J. C., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034110 · Cited by 17
Self-citationOrofacial pain in 1916 patients with early or moderate Parkinson disease
O’Neill, F., Kobylecki, C., Carrasco, R., Hu, M. T., Grosset, D. G., & Silverdale, M. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000923 · Cited by 17
Self-citationUniversal clinical Parkinson’s disease axes identify a major influence of neuroinflammation
Sandor, C., Millin, S., Dahl, A., Schalkamp, A., Lawton, M., Hubbard, L., Rahman, N., Williams, N. M., Ben‐Shlomo, Y., Grosset, D. G., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01132-9 · Cited by 16
Self-citationProfiling cognitive and neuropsychiatric heterogeneity in Parkinson’s disease
van Balkom, T. D., Vriend, C., Berendse, H. W., Foncke, E. M. J., van der Werf, Y. D., van den Heuvel, O. A., & Klein, M. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.05.014 · Cited by 16
Digital biomarkers in Parkinson’s disease
Bougea, A. M. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.005 · Cited by 16
Challenges and Potential of Using Digital Biomarkers in Healthcare and Clinical Trials
Lieberwirth, J. K., Mittermaier, M., & Stern, A. D. (2026) · Communications Medicine · doi:10.1038/s43856-026-01450-8 · Cited by 13
Lawton, M., Tan, M. M. X., Ben‐Shlomo, Y., Baig, F., Barber, T. R., Klein, J. C., Evetts, S. G., Millin, S., Malek, N., Grosset, K. A., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327376 · Cited by 13
Self-citationPrecision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells
Kim, M. S., Kim, H., & Lee, G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303041 · Cited by 12
Tsanas, A., & Arora, S. (2022) · SN Computer Science · doi:10.1007/s42979-022-01123-y · Cited by 12
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 12
Research-ready data: the C-Surv data model
Bauermeister, S., Bauermeister, J. R., Bridgman, R., Felici, C., Newbury, M., North, L., Orton, C., Squires, E., Thompson, S., Young, S., et al. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-022-00916-y · Cited by 11
Kverneng, S. U., Stige, K. E., Berven, H., Mostafavi, S., Lundervold, K., Brischigliaro, M., Brakedal, B., Skeie, G. O., Flønes, I. H., Toker, L., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00817-7 · Cited by 11
Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression
Rabey, J. M., Yarden, J., Dotan, N., Mechlovich, D., Riederer, P. F., & Youdim, M. B. H. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02194-y · Cited by 10
Samantaray, T., Saini, J. S., & Gupta, C. N. (2022) · Neuroscience Informatics · doi:10.1016/j.neuri.2022.100100 · Cited by 10
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Bowring, F., Welch, J., Woodward, C., Lo, C., Lawton, M., Sulzer, P., Hanff, A.-M., Krüger, R., Liepelt‐Scarfone, I., & Hu, M. T. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-049530 · Cited by 9
Self-citationNon-motor Subtypes of Parkinson’s Disease and Sleep Dysfunction
Leta, V., Tosi, M., Chen, R., Jost, S. T., Dafsari, H. S., Popławska-Domaszewicz, K., Chaudhuri, К. R., & Sauerbier, A. (2025) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2025.06.007 · Cited by 8
Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease
Picillo, M., Barone, P., & Pellecchia, M. T. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12521 · Cited by 8
Personalized event prediction for Electronic Health Records
Lee, J. M., & Hauskrecht, M. (2023) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2023.102620 · Cited by 7
Pachi, I., Papadopoulos, V., Koros, C., Simitsi, A., Bougea, A. M., Bozi, M., Papagiannakis, N., Soldatos, R. F., Kolovou, D., Pantes, G. V., et al. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230056 · Cited by 7
Smartphone Sensing Technologies for Tailored Parkinson’s Disease Diagnosis and Monitoring
Postolache, G. B., & Postolache, O. A. (2018) · EAI/Springer Innovations in Communication and Computing · doi:10.1007/978-3-319-93491-4_13 · Cited by 6
Environmental and genetic risk factors for Parkinson's disease
Belbasis, L., Bellou, V., & Εvangelou, Ε. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00004-1 · Cited by 6
Zeissler, M., Boey, T., Chapman, D., Rafaloff, G., Dominey, T., Raphael, K. G., Buff, S., Pai, H. V., King, E., Sharpe, P., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071641 · Cited by 5
Hani, M., Mahmoudi, S., & Benjelloun, M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107435 · Cited by 3
Zeissler, M., McFarthing, K., Raphael, K. G., Rafaloff, G., Windle, R. J., & Carroll, C. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230109 · Cited by 3
Kverneng, S. U., Mostafavi, S., Mikhaleva, Y., Johanson, G. A. S., Berven, H., Lundervold, K., Skeie, G. O., Sheard, E., Søgnen, M., Geijerstam, S. A. A., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251365253 · Cited by 2
Dashtipour, K., Vakhshoori, M., Hashempour, Z., Espay, A. J., Ghamsary, M., Jones, J., Pedouim, F., Frei, K. P., & Baghaei, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100437 · Cited by 2
Rubio, C., Pérez-Rubio, R., Pérez-Villavicencio, J., Serrano‐García, N., Lee, Á., Granados-Rojas, L., Tena‐Suck, M. L., & Rubio‐Osornio, M. (2026) · Life · doi:10.3390/life16061007 · Cited by 2
Boz, H. E., Kiriş, A. Ö., Koçoğlu, K., Çolakoğlu, B. D., Çakmur, R., & Akdal, G. (2021) · Neurological Sciences and Neurophysiology · doi:10.4103/nsn.nsn_148_20 · Cited by 2
The role of ADAR editing and nonsense-mediated decay in Parkinson’s DiseasePreprint
Mercer, H., Nair, A. M., Tariq, A., & Piontkivska, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.17.594716 · Cited by 2
Variations in ADAR editing of nonsense-mediated decay targets in PD males and females
Mercer, H., Nair, A. M., Tariq, A., & Piontkivska, H. (2025) · F1000Research · doi:10.12688/f1000research.168181.1 · Cited by 1
Yadav, R., Mahale, R. R., & Pal, P. K. (2018) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_7_18 · Cited by 1
Sandor, C., Millin, S., Dahl, A., Lawton, M., Hubbard, L., Bojovic, B., Guzzon, M. P., Matten, H., Blancher, C., Williams, N. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/655217 · Cited by 1
Self-citationResearch consortium offers new hope for Parkinson's disease
Buckland, D. (2016) · Prescriber · doi:10.1002/psb.1474
Biomarkers for Parkinson’s disease and Alzheimer’s disease
Liu, B. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-v0jeab0e0
Baig, F. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-6qemzn76z
Self-citationA Bayesian Evaluation of Subtyping Methods in Parkinson’s Disease
Johnson, A. R. (2019) · eSpace (Curtin University)
Parkinson’s disease subtypes: literature review
Diachenko, P. Y., & Moskovko, G. S. (2020) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2020-24(3)-23
Parkinson’s Disease and Parkinsonian Tremor
Dirkx, M. F., & Helmich, R. C. G. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197529652.003.0012
Metadata
- Authors
- Lawton, M., Baig, F., Rolinski, M., Ruffman, C., Nithi, K., May, M. T., Ben-Shlomo, Y., & Hu, M. T. M.
- Affiliations
- University of Bristol (GB)
- University of Oxford (GB)
- Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK
- John Radcliffe Hospital (GB)
- School of Social and Community Medicine, University of Bristol, Bristol, UK
- Corresponding author
- Hu, Michele T.M.
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-06-01
- Volume
- 5
- Issue
- 2
- Pages
- 269-279
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC4923737
- OpenAlex
- W1581756795
- Cited by
- 100
- References
- 38
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 11 · 2021: 8 · 2020: 12 · 2019: 14 · 2018: 15 · 2017: 8 · 2016: 6 · 2015: 1
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, cc-by-nc)
- Bristol Research (University of Bristol) (acceptedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute for Health and Care Research
- Parkinson's UK
- University of Oxford
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, phenotypic subtypes, disease heterogeneity, clustering, REM sleep behavior disorder, cognitive impairment, rigidity, tremor, psychological well-being, non-motor symptoms, early-stage Parkinson's disease
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Phenotype, Cohort Studies, Cluster Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.